Emprise Bank Has $268,000 Holdings in Eli Lilly and Company $LLY

Emprise Bank cut its stake in shares of Eli Lilly and Company (NYSE:LLY) by 37.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 344 shares of the company’s stock after selling 204 shares during the period. Emprise Bank’s holdings in Eli Lilly and Company were worth $268,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. WestEnd Advisors LLC grew its stake in shares of Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock worth $26,000 after purchasing an additional 21 shares during the period. Wealth Preservation Advisors LLC bought a new position in Eli Lilly and Company during the first quarter worth about $27,000. Citizens National Bank Trust Department lifted its holdings in Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock worth $35,000 after acquiring an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. bought a new position in Eli Lilly and Company during the first quarter worth about $40,000. Finally, TD Capital Management LLC lifted its holdings in Eli Lilly and Company by 129.2% during the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after acquiring an additional 31 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CEO David A. Ricks bought 1,632 shares of the firm’s stock in a transaction dated Tuesday, August 12th. The shares were bought at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the transaction, the chief executive officer owned 546,601 shares of the company’s stock, valued at $352,431,926.77. This trade represents a 0.30% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Daniel Skovronsky bought 1,000 shares of the firm’s stock in a transaction dated Tuesday, August 12th. The stock was purchased at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the transaction, the executive vice president directly owned 137,660 shares of the company’s stock, valued at $87,331,504. The trade was a 0.73% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired 4,514 shares of company stock valued at $2,894,841 in the last ninety days. 0.14% of the stock is currently owned by company insiders.

Eli Lilly and Company Stock Down 0.9%

LLY stock opened at $748.26 on Tuesday. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The firm has a market capitalization of $708.20 billion, a PE ratio of 48.91, a PEG ratio of 1.05 and a beta of 0.47. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $939.86. The business’s 50 day simple moving average is $740.54 and its 200 day simple moving average is $774.30.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. The business had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm’s revenue was up 37.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th were given a $1.50 dividend. The ex-dividend date of this dividend was Friday, August 15th. This represents a $6.00 annualized dividend and a dividend yield of 0.8%. Eli Lilly and Company’s dividend payout ratio is presently 39.22%.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Daiwa Capital Markets lowered Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 target price on the stock. in a report on Sunday, August 17th. Erste Group Bank lowered Eli Lilly and Company from a “buy” rating to a “hold” rating in a report on Thursday, June 5th. Guggenheim reduced their target price on Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating on the stock in a report on Wednesday, August 13th. Daiwa America lowered Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 17th. Finally, Wall Street Zen upgraded Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 30th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $941.35.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.